MOTS-c vs Retatrutide

The Dose Guy’s verdict

Oct 27, 2026
12 sources

For fat loss, retatrutide, and it is not a contest. Retatrutide is the strongest weight-loss drug with human trial numbers behind it; MOTS-c has never been tested as a dose in a person, and its fat data is mice. MOTS-c has a different job, an experiment in holding energy up during a deficit or around fasted cardio. If you want to try it, it rides alongside a retatrutide cut, never in place of one.

Which would I take?Reta for the fat. MOTS-c is a side project.

How they differ

The gap is evidence, and it is most of the page. Retatrutide works three receptors, GLP-1, GIP, and glucagon: hunger goes quiet, meals sit longer, and the glucagon arm spends extra energy on top. You feel it within weeks, and the trials measured it. MOTS-c is a short peptide your own mitochondria make, a signal that flips the cell’s energy sensor, AMPK, when fuel runs short. In mice it kept fat off and kept old animals running. In people, nobody has published a trial of injecting it, so if the scale moves on MOTS-c alone, the diet is the likelier cause.

So they do not compete for the same slot. Retatrutide is the cut. MOTS-c, if you want it, is a short add-on aimed at the flat, low-energy feeling a deep deficit brings, timed around fasted training. That is the one use I find genuinely interesting, and it is still a guess with a syringe. If you are already lean, neither is the call: tirzepatide handles the last few kilos with an appetite you can still train on.

The rhythm differs too. Retatrutide is one pin on one day a week, judged by your hunger. MOTS-c is several pins a week, usually on training mornings, and you judge it by how the sessions feel, not by the scale.

What the research shows

No trial has compared them, and only one side has human trials at all:

No trial has compared MOTS-c with retatrutide, and no controlled human trial has tested injected MOTS-c for efficacy or safety.as of Aug 2026

Retatrutide 12 mg: 24.2% mean weight loss at 48 weeks, versus 2.1% on placebo, with 83% of that arm losing at least 15%.NEJM 2023 · phase 2 · n=338

MOTS-c treatment in mice prevented diet-induced obesity, along with the insulin resistance that comes with age and a high-fat diet.Cell Metab 2015 · discovery · mouse

MOTS-c enhanced physical performance in young, middle-aged, and old mice; treatment begun at 23.5 months increased physical capacity and healthspan.Nat Commun 2021 · mouse aging

In adipose-derived stromal cells from six donors with obesity, exogenous MOTS-c reduced proliferation and increased p16, p21, and TNF-alpha expression, markers of cells heading into senescence. A dish, not a person.Inflamm Regen 2026 · in vitro

Note what the mouse result is. Those mice were kept from gaining, not put on a cut and measured losing.

How people run them

Retatrutide runs the way it always does: one weekly sub-q pin, dosed to your hunger. Start at 1 or 2 mg, hold while appetite stays quiet, and raise only when real hunger returns, a month per change. Skip alcohol on it, keep protein high, and keep lifting.

MOTS-c has no studied human dose, so there is nothing to defend with data. The community runs 5 to 10 mg sub-q two to four times a week, often before fasted training. That is forum consensus, not a result. If you add it to a retatrutide cut, wait until your retatrutide dose has settled, so a rough week has one suspect, and run it for weeks, not months. Both drugs touch how your body handles blood sugar and nobody has studied the pair, so if fasted sessions on both leave you shaky or light-headed, eat first and drop the MOTS-c.

There is no switching between them, because they are not doing the same job. If you ran MOTS-c hoping for fat loss and the scale held still, that is the expected result. Start retatrutide whenever you like; there is nothing to taper.

Retatrutide1–2 mg/wk startDose to hunger; plenty of people hold in the low single digits.

The stack+ MOTS-c, shortOnly once your retatrutide dose is steady, so a bad week has one suspect.

Starting reta1–2 mg, any dayComing off MOTS-c, there is nothing to taper and no washout to wait out.

Side effects, side by side

Retatrutide’s sides are measured; MOTS-c’s are mostly unknown:

commonNausea, sluggish digestion, and the odd rough day of vomiting or constipation on retatrutide, clustered around dose raises. Slower raises fix most of it.

monitorResting heart rate ticks up a few beats on retatrutide, the glucagon arm’s tell. Check yours now and then; in the trials it rose early and eased with time.

anecdotalNight sweats and running warm on retatrutide, reported widely. Injection-site irritation on MOTS-c, reported at standard sub-q volumes.

unknownMOTS-c works the same energy sensor metformin does. Whether injected doses move blood sugar is unknown, and fasted training on top of retatrutide is where to watch for it.

unknownNo human safety data exists for injected MOTS-c. The senescence signal in the cell study is reason enough to keep courses short.

monitorRetatrutide shares the GLP-1 class’s small pancreatitis risk. Upper-belly pain that is severe and will not ease means stop the pin and get seen that day.